The Importance of ‘Disclosure’ in Relationships between Physicians and Pharmaceutical Companies
DOI:
https://doi.org/10.18778/1899-2226.20.1.07Keywords:
conflict of interest, disclosure, ethical standard, pharmaceutical industryAbstract
The article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers.
References
Advamed, The Physician Sunshine Act and You, http://advamed.org/res.download/60.
Google Scholar
Agrawal S., N. Brennan, P. Budetti, The Sunshine Act–effects on physicians, „New England Journal of Medicine” 2013, vol. 368, nr 22, s. 2054–2057.
Google Scholar
American Medical Association, Sunshine Act FAQs, http://www.ama-assn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financial-transparency-reports/sunshineact-faqs.page?.
Google Scholar
Campbell E.C., R.L. Gruen, J. Mountford, L.G. Miller, P.D. Cleary, D. Blumenthal, A National Survey of Physician – Industry Relationships, „The New England Journal of Medicine” 2007, nr 356, s. 1746.
Google Scholar
CBOS, Prestiż zawodów, Warszawa 1999.
Google Scholar
CBOS, Prestiż zawodów, Warszawa 2013.
Google Scholar
CBOS, Społeczne oceny uczciwości i rzetelności zawodowej, Warszawa 2016.
Google Scholar
Ciadini R., Wywieranie wpływu na ludzi. Teoria i praktyka, GWP, Gdańsk 2003.
Google Scholar
CMS, Fact Sheet for Physcians, https://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/Downloads/Physician-fact-sheet.pdf.
Google Scholar
CMS, Open Payments Data Summary, https://openpaymentsdata.cms.gov/summary.
Google Scholar
The CMS Blog, CMS Releases Third Year of Open Payments Data, https://blog.cms.gov/2016/06/30/cms-releases-third-year-of-open-payments-data/.
Google Scholar
Comparison of the French sunshine act. (Loi Bertrand Law) and the US Sunshine Act, https://pharmapromotional.wordpress.com/2013/09/30/comparison-of-the-french-sunshine-act-loi-bertrand-law-and-the-us-sunshine-act/.
Google Scholar
Hajnosz I., H. Wróblewski, To jak pan korumpował lekarza, „Gazeta Wyborcza” 2007, nr 182, s. 6.
Google Scholar
Halperin E.C., P. Hutchison, R.C. Barrier Jr, A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers, „International Journal of Radiation Oncology* Biology* Physics” 2004, nr 59(5), s. 1479.
Google Scholar
INFARMA, Czym jest Kodeks Przejrzystości, http://www.kodeksprzejrzystosci.pl/kodeksprzejrzysto%C5%9Bci/.
Google Scholar
INFARMA, Kodeks Dobrych Praktyk Przemysłu Farmaceutycznego, http://www.infarma.pl/assets/files/etyka/KodeksDobrychPraktyk_Wyd_2_201014_PL.PDF.
Google Scholar
INFARMA, Kodeks przejrzystości, http://www.kodeksprzejrzystosci.pl/assets/files/etyka/Kodeks_Przejrzystosci_wydanie_5.pdf.
Google Scholar
Kruczkowska M., Koncerny farmaceutyczne korumpują Chiny. Jeden się pokajał, „Gazeta Wyborcza” 2013, nr 172, s. 8.
Google Scholar
Lieb K., A. Scheurich, Contact Between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits, „PLoS One” 2014, nr 9 (10), doi: 10.1371/journal.pone.0110130.
Google Scholar
Lizut M., Jak ustawić lekarza, „Gazeta Wyborcza” 2006, nr 120, s. 4.
Google Scholar
Makowska M., Etyczne standardy marketingu farmaceutycznego, CeDeWu, Warszawa 2010.
Google Scholar
Makowska M., Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce, Wydawnictwo SGGW, Warszawa 2016.
Google Scholar
Makowska M., Rola śledztw dziennikarskich w kreowaniu etycznych standardów marketingu farmaceutycznego, „Prakseologia” 2012, nr 152.
Google Scholar
Orlowski J.P., L. Wateska, The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch, „Chest” 1992, nr 102(1), s. 270–271.
Google Scholar
PolicyMed, Open Payments Data Summary, http://www.policymed.com/2016/06/open-payments-2015-data-released.html.
Google Scholar
Pham-Kanter G.G., Alexander C., Nair K., Effect of Physician Payment Disclosure Laws on Prescribing, „Archives of Internal Medicine” 2012, nr 172, s. 819.
Google Scholar
Prozilo Life Sciences, Ready or Not, Full Speed Ahead for the Global Transparency Movment, https://s3-us-west-2.amazonaws.com/porzio/media/1432/porziols-whitepaper_august-2015.pdf.
Google Scholar
Rabij M., Lekarz zdalnie sterowany, „Newsweek Polska” 2014, nr 2, s. 32–35.
Google Scholar
Raport przejrzystości, http://www.kodeksprzejrzystosci.pl/raporty/.
Google Scholar
Snapshot of sunshine rules in EU countries for the pharmaceutical industry, http://documents.jdsupra.com/beee41ce-968c-484e-9eca-73d39615efb1.pdf.
Google Scholar
Szymborski T., Kasa fundacji zabytków, „Rzeczpospolita” 2003, nr 123, s. A1–A4.
Google Scholar
Vox, Doctors and hospitals got at least $3.5 billion from industry in just five months, http://www.vox.com/2014/9/30/6868897/you-can-now-search-for-your-doctors-pharmapayments-online-sunshine-act.
Google Scholar
Wazana A, Physicians and the Pharmaceutical Industry. Is a Gift Ever Just a Gift?, „Journal of American Medical Association” 2000, vol. 283, nr 3, s. 375.
Google Scholar
Zverejňovanie na základe zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach, http://www.nczisk.sk/Medicinska-statistika/Zverejnovanie_na_zaklade-zakona_362-2011_liekoch_zdravotnickych_pomockach/Stranky/default.aspx.
Google Scholar
